CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
887 results found-
The full year fixed reward for P Perreault was US$1,856,133, the full year cash STI payment was US$2,262,385 and the full year share based payment expense was US$3,654,625.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
CSL was originally established by the Australian government in As at 30 June 2021, the CSL Group employed over 25,000 full 1916 for the purpose of supplying Australia with vaccines and time equivalents (FTE) and delivered medicines to patients other bacteriological products.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2021.pdf -
In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D. This includes growing CSL R&D's footprint in Melbourne, Australia
https://newsroom.csl.com/2022-11-02-Next-Generation-mRNA,-Gene-Therapy,-Plasma-Products,-Monoclonal-Antibodies,-and-Recent-Acquisitions-and-Collaborations-Highlight-CSL-R-D-Day-2022 -
This is a preliminary data picture from the trial, and we will use additional time to analyze the full data set with our partner Travere," said Steve Pascoe, MD, Senior Vice President, Clinical and Therapeutic Area Strategy, CSL. "
https://newsroom.csl.com/2023-05-02-Topline-Results-from-Two-Year-Primary-Efficacy-Endpoint-in-Pivotal-Phase-3-DUPLEX-Study-of-Sparsentan-in-Focal-Segmental-Glomerulosclerosis -
Whilst plasma including 5,000 m2 of lab space and can accommodate about collections were adversely impacted in the prior year due to 300 full-time employees.
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2021-22.pdf -
CSL's Code of Responsible Business Practices guides our interactions with stakeholders and sets expectations for responsible business conduct.
https://www.csl.com/sustainability/governance/ethics-and-transparency -
Please see full prescribing information for Hizentra, including boxed warning and the patient product information .
https://newsroom.csl.com/2024-01-03-CSL-Behring-Announces-Availability-of-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-10g-Prefilled-Syringe -
The one-year collaboration concluded in April 2021 after a Phase III clinical trial of the potential therapy did not meet its endpoints.
https://newsroom.csl.com/2021-09-17-CSL-Behrings-Global-Role-in-Battling-COVID-19 -
CSL engages stakeholders and periodically undertakes a formal materiality assessment process to understand our relevant sustainability-related topics.
https://www.csl.com/sustainability/governance/stakeholder-engagement-and-material-topics